Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASCERN: Dasatinib vs Imatinib in CML with Suboptimal Response
NCT01593254Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2012
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 2 trial of dasatinib in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Sep 2012; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01593254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593254.